Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Slides:



Advertisements
Similar presentations
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.
Advertisements

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Individualizing Therapy for Gastrointestinal Malignancies 2010 Update
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
Presented By Alan Venook at 2016 ASCO Annual Meeting
Managing Colon cancer in the era of molecular markers
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)  D.P. Modest, I. Ricard,
CCO Independent Conference Coverage
Correlation of tumor mutation burden and chemotherapy outcomes
Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.
Copyright © 2010 American Medical Association. All rights reserved.
Presented By Michael Lee at 2016 ASCO Annual Meeting
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.
MCW Regional Cancer Therapy Program
Fondazione Poliambulanza - Brescia
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.
CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES Cheng I1, Hertz.
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
BRAF mutant mCRC patients – What would you recommend? FOLFIRINOX/Bev
Challenges in RAS Wild-Type mCRC
New ESMO Guidance on Tumor Sidedness in mCRC
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms
Fundamental Concepts in the Diagnosis of Advanced NSCLC
New Patient Journeys in Non-small cell lung cancer
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
Axel Grothey Professor of Oncology Mayo Clinic Rochester
Alan P. Venook, MD University of California, SF
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?
Best Practices in Metastatic Colorectal Cancer
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Progression-Free Survival Times Overall Survival Times
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.
Published online September 20, 2017 by JAMA Surgery
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.
Discussion on Abstracts 362, 363, 364, 365, and 366 or…We still have a lot to learn about colorectal cancer Johanna Bendell, MD Director, GI Oncology Research.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Targeted Therapies for Hepatocellular Carcinoma
Raymond N. DuBois, M.D., Ph.D. Executive Director
Ali Shamseddine,MD,FRCP
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
CRC-TREATMENT BEYOND SECOND LINE
Preoperative/neoadjuvant treatment of CRC liver metastases
Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
MSI.
The Nurse View.
Oral Presentation, NAACCR/IACR
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
MET amplification is selected in KRAS wild-type colorectal cancer samples from patients who developed resistance to anti-EGFR treatment. MET amplification.
Schema of the exploratory analyses (RAS wild-type population)
Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.
Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.
Updates in Best Practices in Non-Small Cell Lung Cancer
Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.
Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.
Presentation transcript:

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Disclosures

Improvement in Outcomes: Metastatic Colon Cancer

CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

Metastatic Colorectal Cancer

FIRE-3: Overall Survival in All RAS WT

Metastatic Colorectal Cancer

A Proven Biomarker: Pan-RAS Testing for Anti-EGFR Therapy

KRAS Mutations

KRAS and Front Line anti-EGFR

Pan-RAS Mutations and anti-EGFR

Highly Promising Biomarkers: Testing for MSI and HER-2 amplification

Immunotherapy for MMR-Deficient Cancers

HER-2 Targeted Therapy for GE AdenoCa

HER-2 Targeted Therapy for CRC

Summary - “Standard of Care” Testing for CRC

Thank You

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.